88IV - PR Newswire Asia's news


Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics SEONGNAM, South Korea , Aug. 24, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D SHANGHAI and HONG KONG , Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion TAIPEI , Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that ... 2026-08-24T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? BEIJING , Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy NANJING, China , Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
/C O R R E C T I O N -- Akeso, Inc./ In the news release, Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline, issued 21-Aug-2026 by Akeso, Inc. over PR Newswire, we are ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology